Combination therapy for treating her2-positive cancers
AssigneeMerrimack Pharmaceuticals, Inc.
InventorsVictor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
Life of this patent
Estimating the term…
Abstract
Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
Claims25
1-28. (canceled)
A method of treating a patient with breast cancer that overexpresses HER2, the method comprising administering to the patient, a HER2 directed therapy consisting of:
- an initial dose of 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes and 8 mg/kg trastuzumab, followed by the administration to the patient once every three weeks of 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in the MM302 doxorubicin HER-2 targeted immunoliposomes and 6 mg/kg trastuzumab, to treat the breast cancer.
A method of treating a patient susceptible to or diagnosed with locally advanced/unresectable breast cancer or metastatic advanced breast cancer having a HER2 immunohistochemistry (IHC) score of HER2 2+ or HER2 3+, the method comprising administering to the patient:
- a. 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 8 mg/kg trastuzumab, followed by
- b. administering to the patient once every three weeks 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 6 mg/kg trastuzumab, to treat the locally advanced/unresectable or metastatic advanced breast cancer.
A method of treating a patient susceptible to or diagnosed with locally advanced/unresectable breast cancer or metastatic advanced breast cancer characterized as being HER2 FISH positive, the method comprising administering to the patient:
- a. 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 8 mg/kg trastuzumab, followed by
- b. administering to the patient once every three weeks 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 6 mg/kg trastuzumab, to treat the locally advanced/unresectable or metastatic advanced breast cancer.
Dependencies are inferred from the claim text.